As an indication of things to come, Qiagen (Venlo, The Netherlands) signed an exclusive agreement with Johns Hopkins University to license the P13K gene test which indicates four growth factor mutations in pathways of several human cancers.  Where those mutations are present, chemotherapies for breast, colon, lung, ovarian, liver and stomach cancers may not work.  Thus, this companion diagnostic rules out certain drugs that likely would be ineffectual.  Qiagen paid Hopkins $95m for this license, with another $35m depending on Qiagen’s success with it.  MORE